

Table 1. Main patient characteristics of the derivation Chinese cohort and external validation cohorts

Variables	Country						P value
	Derivation cohort (N=390)	French cohort (N=448)	Turkish cohort (N=172)	Malaysian cohort (N=270)	Egyptian cohort (N=61)	Spanish cohort (N=138)	
Demographics							
Age (years)	41·06±11·98	57·45±11·68	48·43±11·15	52·57±11·36	44·79±9·16	52·72±10·92	P<0.05
Sex (male)	299 (76·7%)	278 (62·1%)	91 (52·9%)	137 (50·7%)	21 (34·4%)	54 (39·1%)	P<0.05
Body measurements							
Height (cm)	167·90±8·39	167·53±9·60	164·5±11·00	161·12±8·71	165·80±7·29	166·70±9·72	P<0.05

Weight (kg)	76.25±13.39	93.50±19.69	90.84±16.51	78.64±14.82	93.86±13.23	89.35±18.12	P<0.05
BMI (kg/m ²)	26.92±3.35	33.26±6.17	33.53±4.91	30.21±4.64	34.07±4.68	32.00±5.38	P<0.05
Waist circumference (cm)	91.97±8.76	113.13±14.74	108.33±10.91	98.71±10.75	108.43±12.25	105.13±12.85	P<0.05
WHR	0.92±0.06	1.03±0.09	0.98±0.07	0.93±0.07	NA	NA	/

Laboratory parameters

AST (U/L)	46.49±31.98	44.59±32.69	51.55±36.12	43.65±23.51	48.30±40.04	50.52±28.49	P=0.06
ALT (U/L)	76.78±72.98	61.18±39.36	79.66±65.81	66.55±42.29	55.75±34.43	76.48±47.40	P<0.05
Alkaline phosphatase (U/L)	85.36±29.29	77.69±28.78	88.92±46.59	82.39±30.88	108.55±41.03	106.19±59.70	P<0.05
Albumin (g/L)	46.39±3.88	42.73±3.56	45.35±3.58	42.16±3.76	4.15±0.45	44.45±4.34	P<0.05

Platelet count (x10 ⁹ /L)	244.81±57.98	223.16±64.32	227.44±64.79	271.00±69.28	245.95±68.82	228.57±61.74	P<0.05
Fasting glucose (mmol/L)	5.69±1.54	7.00±2.54	6.63±2.12	6.96±2.59	NA	6.94±2.81	P<0.05
HbA1c (%)	6.12±1.38	6.49±1.21	6.25±1.20	6.97±2.44	6.60±0.85	6.59±1.48	P<0.05
Creatinine (μmol/L)	67.15±14.24	72.01±15.60	67.34±15.55	73.05±19.16	66.85±16.03	71.76±14.80	P<0.05
e-GFR (CKD-EPI)	110.37±14.46	92.68±15.73	101.67±14.66	92.52±20.80	100.11±19.18	89.22±18.55	P<0.05
Total bilirubin (μmol/L)	14.25±6.62	11.19±6.60	16.38±14.75	11.89±6.41	13.02±6.00	12.13±7.99	P<0.05
Total cholesterol (mmol/L)	5.10±1.16	4.94±1.22	NA	4.77±1.10	5.65±1.22	5.09±1.31	P<0.05
Triglycerides (mmol/L)	2.28±1.37	1.91±1.22	2.03±1.06	1.71±0.83	1.89±0.84	1.85±0.97	P<0.05

Concomitant diseases

Hypertension (%)	126 (32.3%)	315 (70.3%)	77 (44.8%)	168 (62.2%)	21 (34.4%)	50 (36.2%)	P<0.05
Type 2 diabetes (%)	111 (28.5%)	231 (51.6%)	93 (54.1%)	209 (77.4%)	15 (24.6%)	58 (42.0%)	P<0.05
Non-invasive models							
ION	55.85±72.06	107.97±239.94	61.04±45.67	/	/	/	/
Histological characteristics							
Steatosis							P<0.05
1	156 (40.0%)	214 (47.8%)	25 (14.5%)	80 (29.6%)	23 (37.7%)	47 (34.1%)	
2	94 (24.1%)	137 (30.6%)	62 (36.0%)	148 (54.8%)	22 (36.0%)	54 (39.1%)	
3	140 (35.9%)	97 (21.7%)	85 (49.4%)	42 (15.6%)	16 (26.2%)	37 (26.8%)	

Ballooning

P<0.05

0	37 (9.5%)	93 (20.8%)	6 (3.5%)	67 (24.8%)	35 (57.4%)	63 (45.7%)
1	210 (53.8%)	215 (48.0%)	86 (50.0%)	139 (51.5%)	19 (31.1%)	61 (44.2%)
2	143 (36.7%)	140 (31.3%)	80 (46.5%)	64 (23.7%)	7 (11.5%)	14 (10.1%)

Lobular inflammation

P<0.05

0	23 (5.9%)	70 (15.6%)	3 (1.7%)	3 (1.1%)	32 (52.5%)	47 (34.1%)
1	285 (73.1%)	325 (72.5%)	67 (39.0%)	168 (62.2%)	13 (21.3%)	75 (54.3%)
2	79 (20.3%)	53 (11.8%)	69 (40.1%)	96 (35.6%)	16 (26.2%)	14 (10.1%)
3	3 (0.8%)	0	33 (19.2%)	3 (1.1%)	0	2 (1.4%)

NAS	4.39±1.41	3.80±1.38	5.55±1.54	4.22±1.31	4.77±1.37	3.36±1.48	P<0.05
Fibrosis stage							P<0.05
0	114 (29.2%)	47 (10.5%)	NA	71 (26.3%)	NA	46 (33.3%)	
1	191 (49.0%)	98 (21.9%)	NA	115 (42.6%)	NA	33 (23.9%)	
2	65 (16.7%)	132 (29.5%)	NA	22 (8.1%)	NA	25 (18.1%)	
3	14 (3.6%)	135 (30.1%)	NA	53 (19.6%)	NA	27 (19.6%)	
4	3 (0.8%)	36 (8.0%)	NA	9 (3.3%)	NA	7 (5.1%)	

Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, BMI = body mass index, e-GFR = estimated glomerular filtration rate, GGT = γ -glutamyl transferase, HbA1c = glycated hemoglobin, HOMA-IR = homeostasis model assessment of insulin resistance, NA = not available, NAS = NAFLD activity score, P3NP = procollagen-3 N-terminal peptide, WHR = waist to hip ratio.

Notes: Inter-group difference analysis of continuous variables was evaluated by one-way ANOVA analysis and of categorical variables was evaluated by chi-square test.